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While many core JAK/STAT pathway components have been discovered in Drosophila via classical genetic
approaches, the identiﬁcation of pathway regulators has been more challenging. Recently two cell-based
RNAi screens for JAK/STAT pathway regulators have been undertaken using libraries of double-stranded
RNAs targeting a large proportion of the predictedDrosophila transcriptome.While both screens identiﬁedenome-wide screen
ell culture
uciferase reporter
rosophila
multiple regulators, only relatively few loci are common to both data sets. Here we compare the two
screens and discuss these differences. Although many factors are likely to be contributory, differences in
the assay design are of key importance. Low levels of stimulation favouring the identiﬁcation of negative
pathway regulators and high levels of stimulation favouring the identiﬁcation of positively acting factors.
Ultimately, the results from both screens are likely to be largely complementary and have identiﬁed a
range of novel candidate regulators of JAK/STAT pathway activity as a starting point for new research
directions in the future.
© 2008 Elsevier Ltd.
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.1. The JAK/STAT pathwayThe JAK/STAT signal transduction pathway has been conserved
hrough evolutionary time and, while most intensively studied in
ertebrate models, a ‘core’ signalling pathway with homologues
f the main pathway components is also present in the fruit ﬂy
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rosophila melanogaster. These include a trans-membrane receptor
ermed Domeless (Dome) with structural homology to members
f the vertebrate IL-6R family including LIFR and gp130 [1,2], a
eceptor-associated Janus Kinase (JAK) termed Hopscotch (Hop;
3]) and a Signal Transducer and Activator of Transcription (STAT)
ermed STAT92E [4,5] (Fig. 1). Three secreted ligands termed
npaired (Upd), Unpaired 2 (Upd2) and Unpaired 3 (Upd3) have
lso been identiﬁed and shown to have both distinct and over-
apping functions in a range of developmental processes [6–8],
lthough they have only limited homologies to vertebrate STAT
athway ligands.
In addition to these core components, a number of puta-
ive JAK/STAT pathway regulators have also been identiﬁed in
rosophila on the basis of their homology to genes originally char-
cterised in vertebrates. These includemembers of the suppressors
f cytokine signalling (SOCS) family and a protein inhibitor of acti-
ated STAT (PIAS) gene. In Drosophila the three SOCS-like genes
ocs36E, socs16D and socs44A are found. Of these, the homologue to
uman SOCS5, SOCS36E, is best characterised and is both a path-
ay target gene and negative regulator of pathway activity [9,10]. A
rosophila PIAS homologue has also been identiﬁed and shown to
egatively regulate JAK/STAT signalling [11]. More recently, PIAS
roteins have been shown to function as E3 SUMO ligases [12].
lleles of Su(var)2–10, a class of mutations originally identiﬁed as
uppressors of eye colour variegation in Drosophila, and proposed
o be regulators of chromatin structure, have also been identiﬁed as
llelic to dPIAS [13]. Although detailed analysis is still needed, PIAS-
roup proteins may therefore represent more general regulators of
ranscription [14,15].
The conservation of the core JAK/STAT pathway components,
hrough the ∼500 million years that have elapsed since the last
ommon insect/vertebrate ancestor, probably reﬂects essential
oles played by the pathway during development and homeostasis.
or example, physiological roles for the pathway in innate immune
esponses [16,17], haematopoiesis [18–20], stem cell maintenance
21–23] and cellular proliferation [24,25] have all been conserved
n both Drosophila and mammalian systems (reviewed in [26]).
Given the fundamental conservation of JAK/STAT pathway sig-
alling at both the component and functional levels, Drosophila
epresents a promising model system to identify novel pathway
omponents and regulators. The fruit ﬂy Drosophila melanogaster is
widely used, developmentally well-characterised and genetically
ractable organism. Extensive collections of both transposon-
ediated and ‘classical’ mutations are available from stock centres27,28] which, in combination with the detailed annotation of the
equenced genome [29,30], allows the rapid analysis of gene prod-
cts and the elucidation of their roles during development. In
articular, the relatively low complexity of the Drosophila genome
esults in low levels of redundancy so allowing the terminal phe-
ig. 1. Outlineof the JAK/STAT signallingpathway indicating theprincipal corepath-
ay components in Drosophila as well as the two pathway target genes used to
enerate pathway responsive reporter constructs (see text for details).
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otypes associated with the removal of a gene of interest to be
etermined and analysed.
.2. Screening approaches to identify novel JAK/STAT regulators
The use of Drosophila as a tool in the analysis of JAK/STAT sig-
alling was initially facilitated by a number of genetic screens
ndertaken to identify genes required for segmentation of the
arval cuticle (Fig. 2A). One particular phenotypic class, initially
haracterised as an ‘atypical gap gene’ [31,32], was subsequently
hown to result from the disruption of JAK/STAT pathway compo-
ents. Mutations in the genes of the pathway ligand Unpaired [31],
he Domeless receptor [1], the Janus Kinase Hopscotch [33] and
TAT92E [4] were all originally identiﬁed on the basis of this dis-
inctive larval cuticle phenotype (Fig. 2B). This phenotype includes
he deletion or fusion of the denticle belts secreted by abdomi-
al segments a4 and a5, reduction in the a8 denticle belt, defects
n the structures that make up the posterior spiracles as well as
spects of the head skeleton (labelled in Fig. 2B). Indeed, tradi-
ional genetic screening approaches have succeeded in identifying
he core components of the canonical Drosophila JAK/STAT path-
ay largely on the basis of these phenotypes. While powerful, this
pproach is however limited as genes with multiple roles in differ-
nt processes, regulatory functions in speciﬁc tissues or functions
equired for oocyte and early embryonic development are unlikely
o be recovered in this way.
One alternative to the screens already undertaken are F1 genetic
nteraction screens (reviewed in [34]). In this approach, tradi-
ional ‘forward’ genetic techniques are used to generate mutations
n which a reduction in gene dosage leads to a visible interac-
ion with a dominant phenotype. One such experimental design,
ermed GMR-upd, has been established to screen for modulators
f JAK/STAT signalling and is based on the dominant eye over-
rowth phenotype caused by constitutive misexpression of the
npaired ligand in the developing eye. While JAK/STAT pathway
ctivity is required for normal Drosophila compound eye develop-
ent (Fig. 2C) [25,35,36], constitutive high-level Upd expression
eads to over-proliferation of undetermined cells within the future
ye which subsequently differentiate to produce an overgrown
dult eye (compare Fig. 2C and D) [25].
A key characteristic of the F1 genetic screen is the fact that
educing the gene dose of known JAK/STAT pathway components
s sufﬁcient to reduce the eye overgrowth induced by GMR-upd.
his results in adults heterozygous for genes of interest with eyes
hat are less severely overgrown than controls (compare Fig. 2D
nd E). By screening for this genetic interaction,mutations in previ-
uslyunknownpathwayregulators canbe identiﬁedandultimately
dentiﬁed. Two large-scale screenshavebeenundertakenusing this
pproach, and have both identiﬁed genes and genomic regions that
odulate the activity of the pathway in vivo [25,37]. One validation
f this approach is the subsequent characterisation of the ken and
arbie (ken) locus [38]. ken mutations were originally identiﬁed as
oderate enhancers of eye overgrowth [25] and shown to encode
transcriptional repressor. In vivo, Ken appears to competitively
ind to a DNA sequence that largely overlaps that recognised by
he STAT92E transcription factor to selectively modulate the tran-
criptional response to pathway stimulation [38]. As such Ken, and
ossibly also its humanhomologueBCL6, represents a novel class of
AK/STAT pathway regulators acting at the DNA level to speciﬁcally
odulate a subset of the pathway-induced transcriptome..3. Reverse genetic screening approaches
While traditional ‘forward’ genetic approacheshave successfully
dentiﬁed both core JAK/STAT pathway components and pathway
362 P. Müller et al. / Seminars in Cell & Developmental Biology 19 (2008) 360–369
Fig. 2. Genetic screens for JAK/STAT pathway components. Wild type (A) and stat92E mutant (B) larval cuticles showing the distinctive defects associated with mutations in
a elts, d
p henoty
r -upd b
H rowth
r
t
t
t
o
t
m
a
c
e
i
b
[
l
c
(
i
t
I
o
p
d
R
s
i
w
u
s
all core JAK/STAT pathway components. These include loss of the a4 and a5 denticle b
osterior spiracles (PS). The stat92E06346mutant shown has a strong segmentation p
escue. The wild type eye of adult Drosophila (C) is signiﬁcantly overgrown in a GMR
owever, removal of one copy of STAT92E is sufﬁcient to reduce the degree of overg
egulators, these approaches have limitations. A powerful alterna-
ive is the use of ‘reverse’ genetics. In reverse genetic approaches,
he activity of deﬁned genes are reduced and the resulting pheno-
ypes analysed. In such an approach, widely used in mouse knock
ut techniques, a gene of interest is targeted for mutation and
he resultant mutant individuals examined for defects. Although
utation of endogenous loci via homologous recombinationmech-
nismshasbeendemonstrated inDrosophila [39], it is still relatively
umbersome to undertake large scale gene knock-out inDrosophila,
specially by comparison to other forward genetics approaches.
An alternative reverse genetic screening approach uses RNA
nterference (RNAi), a widely used tool to silence gene expression
oth in cultured cells and in vivo. First discovered in C. elegans
40], it was shown that silencing by RNAi relies on an ancient cel-
ular response to infection by double-stranded RNA viruses and
an be used to down-regulate gene expression in all metazoa
reviewed in [41]). Indeed, injection of double-stranded (ds) RNAs
nto Drosophila embryos or expression of hairpin dsRNAs from
b
u
t
m
gisruption of a8 denticle belt and the head skeleton (HS) as well as a reduction in the
pe but a PS reduction less severe than a full pathway null, possibly due to paternal
ackground in which the Unpaired ligand is expressed during eye development (D).
(E) and indicates its role as a regulator of JAK/STAT pathway signalling.
ransgenes have both been shown to be effective in vivo [42–44].
ntriguingly, it was subsequently demonstrated that the addition
f long dsRNA to cultured Drosophila cells is sufﬁcient to trigger a
otent down-regulation of target messages [45]. As invertebrates
o not mount an innate cellular response against double stranded
NAviruses, cells do not respond to the dsRNA itself, but rather dice
uch molecules intracellularly to generate a diverse pool of small
nterfering RNAs (siRNAs).
Since the discovery of the long dsRNA effect in Drosophila cells,
hole genome RNAi-based screens in cultured cells have been
ndertaken to study a broad range of cellular phenotypes, from
imple life–death decisions to the study of signalling pathways
nd changes in cell shape [46–48]. Such experiments were enabled
y large-scale libraries of dsRNAs that can be easily synthesised
sing gene-speciﬁc primer pairs to amplify templates for in vitro
ranscription. These libraries often consist ofmore than 20,000 ele-
ents covering a large proportion of all predicted protein coding
enes.More recently, transgenic libraries of hairpinRNAi constructs
evelopmental Biology 19 (2008) 360–369 363
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Fig. 3. Outline of the RNAi assay approaches used by both Baeg and Müller whole
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tably integrated into individual Drosophila stocks have become
vailable [49]. These can be expressed in any tissue using the het-
rologous GAL4/UAS system [50], potentially enabling large-scale
n vivo RNAi screening studies.
Since the transcript targeted is known, RNAi approaches can
e used to rapidly generate lists of candidate genes involved in a
articular process. However, this versatility comes at the cost of a
ertain ‘fuzziness’ of RNAi phenotypes. Given the high-throughput
ature of a genome-wide RNAi screen, it is not possible to conﬁrm
he efﬁciency or degree of target transcript knock down in every
ase. Similarly, proteins that are very stable and which cannot be
epleted within the time-frame of a given experiment may not be
educed to levels where their knock-down becomes phenotypic. In
ddition, gene families that have very homologous sequences, such
s Histones, are frequently inhibited by the same dsRNAs and spe-
iﬁc knock down of different isoforms of a single gene is usually
ot possible. More signiﬁcantly, since the RNAi mechanism relies
n 19–21mer siRNAs, even a diluted but highly efﬁcient matching
iRNA has the potential to cause ‘off-target’ silencing of unintended
enes. Other elements, such as low-complexity regions encoding
epeated amino acid motifs common to multiple transcripts have
lso been shown to induce silencing of unrelated genes [51,52].
Given these considerations, it is clear that both false negatives
nd false positives can arise in any genome-wide RNAi screening
trategy. It is therefore important to keep in mind that hit lists from
rimary RNAi screens are only candidate modiﬁers that have to be
onﬁrmed by independent approaches.
. RNAi screens for JAK/STAT regulators
In recent years, the technology of large-scale RNAi screening
as been applied to the analysis of the JAK/STAT signalling path-
ay, and two genome-wide RNAi screens have been undertaken
n Drosophila tissue culture systems. The ﬁrst, undertaken jointly
n the Boutros and Zeidler laboratories in Germany [53] and the
econd by the Perrimon laboratory in the US [54]. These screens
ill subsequently be referred to as the Müller and Baeg screens,
espectively. In both screens, Drosophila tissue culture cells were
ransfectedwith reporter constructs engineered todriveexpression
f a ﬁreﬂy luciferase gene under the control of a STAT-dependent
romoter (Fig. 3A). Although both groups used essentially the same
ibrary of dsRNA molecules, they used different pathway stimu-
ation conditions, different cell lines and different reporters (see
able 1 for a description of the principal differences between
he two screens). However, both groups set out to use genome-
ide screening technology to identify the key factors regulating
rosophila JAK/STAT signalling in a relatively simple tissue culture
ystem. Indeed, both groups were successful in identifying a con-
iderable number of genes whose knock-down produced robust
nd reproducible interactions not only in cultured cells, but also
n vivo [53,54]. In particular, the core pathway components dome,
op, stat92E and socs36E were identiﬁed in both screens, as was the
rotein tyrosine phosphatase ptp61F, a gene that appears to play
n important role in the negative regulation of pathway activity in
ivo [53,54].
However, despite the similar goals and apparently similar
pproaches of both screens, the total overlap in the published lists
enerated by both groups is surprisingly low—in the range of 5–6%
6of121/90, respectively).An initial comparisonof the twodata sets
uggests that this relatively low level of overlap may result from a
undamental difference in the nature of the regulators identiﬁed in
ach screens.While 73% of the genes identiﬁed in theMüller screen
re positive regulators of pathway activity, over three quarters of
he genes identiﬁed by the Baeg screen represent putative negative
egulators. Although some of these differences may be the result
f
s
a
a
denome screens. (A) STAT responsive (FL) and constitutive (RL) reporter constructs
sed. (B) Hypothetical responses of both reporters to treatment by dsRNAs that
arget a non-interacting gene (non), a positive regulator, a negative regulator and a
on-speciﬁc dsRNA that reduces cell viability.
f normalisation artefacts (see below and Table 2) it is likely that
lternative assay designs and different levels of pathway stimula-
ion may be responsible for much of this bias. These possibilities
re discussed in greater detail below.
.1. The Müller et al. JAK/STAT RNAi screen
TheMüller screen used the haemocyte-like Drosophila Kc167 cell
ine, which is derived from cells in which the JAK/STAT pathway
s active in vivo [19]. In order to sensitise the system, we co-
ransfected the cells with the dsRNA transporter SID-1, which had
een shown to enhance theuptake of RNAi [55]. The JAK/STATpath-
ay reporter was based on the promoter of a previously published
AK/STAT target gene, raf [56], driving the transcription of the ﬁre-
y luciferase gene (FL). To increase sensitivity, wemultimerised the
TAT binding sites in this promoter element to generate a reporter
ith 12 STAT binding sites, which was termed p6x2xDrafLuc. To
nduce the pathway, cells were transfected with a plasmid cod-
ng for the Upd ligand, generating reporter activity ∼70-fold over
asal levels. In order to monitor effects of dsRNAs on cell viability,
e also transfected a reporter, in which the Renilla luciferase (RL)
as constitutively expressedunder the control of an actinpromoter
Fig. 3A).
Having generated a reporter system, we showed that reporter
ctivity can be speciﬁcally modulated by RNAi mediated knock-
own of JAK/STAT pathway components, while remaining unaf-
ected by knockdown of other signalling pathways. Using this
ystem, two parallel genome-wide screens were undertaken using
library of 20,026 dsRNAs targeting approximately 91% of all
nnotated Drosophila genes [57,58]. Five days after treatment with
sRNAs, cells were lysed and the activities of the STAT92E reporter
364 P. Müller et al. / Seminars in Cell & Developmental Biology 19 (2008) 360–369
Table 1
Comparison of JAK/STAT RNAi screens
Experimental condition Baeg Müller
Biological differences
Pathway stimulation Endogenous Upd2 Ectopically expressed Upd-GFP
Cell line S2-NP Kc167
Screening procedure
Coverage of library 21,300 dsRNAs 20,026 dsRNAs
Screening reporter 10xStat92E-luciferase (FL) containing ﬁve
tandem repeats of a 441bp fragment from the
socs36E enhancer (each with four potential
Stat92E binding sites)
p6x2xDrafLuc containing six repeats of a 165 bp
fragment from the raf promoter (each with two
Stat92E binding sites)
Co-reporter pAct-RL pAct-RL
RNA concentration per well 80ng/well 500ng/well
Cells seeded per well of a 384-well plate 40,000 15,000
Transfection of reporter Per well In batch
dsRNA uptake Transfection Bathing + SID-1 dsRNA trans-porter
Time for RNAi 4 days 5 days
Replicate datasets Two Two
Data processing
Data normalisation Fold SD from the plate mean of FL/RL ratio for
each plate
Fold MAD from the plate median of FL channel
for each plate
Selection of positive regulators <2 SD below plate mean <2 MAD below plate median
Selection of negative regulators >3 SD above plate mean >2 MAD above plate median
Exclusion of genes Genes not annotated by BDGP, ribosomal
proteins, proteins involved in RNA processing
and translation
Previously published cell viability modiﬁers,
treatments with high variability between
replicates, treatments with z-scores >2 or <2 in
the RL channel, genes with phenotypes in other
screens
False-positive rate (determined by re-screens of primary hits) 29% 15%
Human homologs of hits 73% 74%
Table 2
Comparison of common results identiﬁed in different JAK/STAT modulator screens
Gene Baeg (FL/RL) Müller (FL) Müller (FL/RL) Human homologue
dome * − − − gp130a
hop * − − − JAK2b,d,g
stat92E * − − − STAT5c,d,g
cdc2 * − − − CDC2d,g
CG11700 * − − NC UBCh
CG17836 * − − − None
apt + + + None
brm * + − − SMARCA2g
CG15563 + − NC None
CG30460 + − NC C8ORF70g
enok * + + + MYST3,dg
hsc70-4 + − NC HSPA8g
ken * + − NC BCL6e
mbl + − NC MBNL1d,g
mor * + − − SMARCC2d,g
proct + − NC None
ptp61F * + + + PTPN1d,g
samuel + − + SAMD11h
socs36E * + + + SOCS5f
ssdp * + + NC SSBP3d,g
Data from Baeg et al. (‘Baeg’) [54] and from Müller et al 2005 (‘Müller’) [53].
Minus symbols (−) indicate down-regulation, plus symbols (+) indicate up-regulation and NC indicates no change of the pathway reporter after RNAi according to the
normalisation approach indicated in the respective columns. FL indicates changes for the pathway reporter, while FL/RL indicate changes of the pathway reporter after
normalization to a co-reporter.
* indicates that the interaction was conﬁrmed by an independent dsRNA [61].
a Domains in the Dome protein have most homology with the IL-6R family of receptors, including gp130 and LIFR [1].
b Binari and Perrimon [3]
c Hou et al. [4].
d Human homologene.
e Arbouzova et al. [38].
f Karsten et al. [10].
g Inparanoid.
h Best reciprocal BLAST search.
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FL) and control plasmids (RL) determined. To calculate the effect
f each dsRNA treatment, the median of FL and RL activities were
alculated independently for each plate and z-scores determined
y calculating how many median absolute deviations (MAD) each
sRNA differed from the plate median [53]. To identify those dsR-
As that speciﬁcally modulated the reporter system, we selected
sRNAs with a signiﬁcant z-score in the FL channel which did not
ave a signiﬁcant z-score in the co-reporter RL channel (schemat-
cally shown in Fig. 3B). To further increase the speciﬁcity of the
creen, hits were also ﬁltered against genes previously identiﬁed in
ther available genome-wide RNAi data sets.
Having identiﬁed a preliminary list of pathway modulating dsR-
As, we then sought to exclude potential artefacts arising from
he use of the multimerised reporter. The putative interactors were
herefore re-tested using a reporter in which FL activity was driven
y a non-multimerised promoter from the JAK/STAT target gene
ocs36E. Ultimately, re-screening and secondary screens conﬁrmed
he effect of 91 dsRNAs targeting 90 genes including the previously
dentiﬁed pathway components dome, hop stat92E and socs36E. Of
hese, approximately one third were negative regulators and two
hirds positive regulators of JAK/STAT pathway activity.
Finally, the cell culture model was used to undertake epista-
is experiments to further categorise positively acting factors. To
dentify dsRNAs that putatively act in the processing of the ligand
r in the binding to the receptor, we compared reporter activ-
ties of cells expressing the Upd ligand to reporter activities of
ells stimulatedwith Upd conditionedmedium. To identify dsRNAs
hat may act upstream or downstream of JAK, we further induced
athway activity in dsRNA-treated cells using expression of the
onstitutively active JAK allele hopTum-L and compared the results
o the treatments with Upd ligand. These experiments indicated
hat most of the positive regulators identiﬁed act downstream of
AK [53].
.2. The Baeg et al. JAK/STAT RNAi screen
In a second RNAi-based screen for JAK/STAT signalling modu-
ators Baeg and colleagues generated a luciferase-based reporter
ontaining multimerised STAT92E binding sites present within
he socs36E enhancer [54,59]. As expected, this reporter, termed
0xStat92E-luciferase (whichactually contains20potential STAT92E
inding sites), reﬂects JAK/STAT signalling activity and was used
n conjunction with a Schneider cell line [60] derivative, S2-NP
54]. Intriguingly, S2-NP cells appear to express sufﬁcient levels
f endogenous pathway ligand to activate signalling. However,
hile Upd is the major JAK/STAT pathway ligand in vivo [7], RNAi
nockdown suggests that it is the closely related Upd2 ligand
hat activates the pathway in S2-NP cells [54]. To compensate for
otential differences in transfection efﬁciency, the 10xSTAT92E-
uciferase reporter activity was normalised to the activity of the
o-transfected co-reporter Act-RL. Using this assay system, S2-NP
ells were transfected with 10xSTAT92E-luciferase reporter (FL) and
ct-RL co-reporter (RL) along with individual dsRNAs on a well-
y-well basis with reporter activities determined 4 days later. For
andidate selection, the plate averages for the ratios of reporter to
o-reporter (FL/RL) were calculated and phenotypes expressed as
he fold standard deviation (SD) from the mean of each given plate.
enes not annotated by BDGP, genes encoding ribosomal proteins
ndgenes coding forproteins involved inRNAprocessing and trans-
ation were excluded from retesting as were genes affecting the
ctin promoter of the co-reporter.
After retesting of the remaining candidates, Baeg and colleagues
dentiﬁed 121 novel genes that regulate JAK/STAT signalling in
rosophila including the previously identiﬁed JAK/STAT pathway
omponents upd2, dome, hop, stat92E and socs36E. By stimulating
f
f
p
t
tmental Biology 19 (2008) 360–369 365
he cells with Upd, Baeg and colleagues further found that 27 of
9 positive regulators had similar phenotypes following activation
y both Upd and Upd2, indicating that these are regulators of a
ore pathway for which stimulation with different ligands has no
nﬂuence. Of the 29 positive regulators tested, 13 (including dome
nd hop) affected phosphorylation levels of STAT92E. Furthermore,
singamicroscopic assay fornuclear translocationof STAT92E, they
ound homologs of ranBP3 and ranBP10 to be involved in nucleo-
ytoplasmic shuttling of STAT92E.
In 2007, Baeg and colleagues further re-assessed their 121 hits
sing independent dsRNAs to exclude potential off-target effect
nduced artefacts [61]. Using the initial dsRNAs present in the
enome-wide screen, 111 of 121 (92%) of the hits could be con-
rmed with 50 of these 111 (i.e. 41% of the initial hits) re-conﬁrmed
sing multiple independent dsRNAs.
. Differences between the Baeg and Müller screens
One fundamental question arising from a comparison of the
aeg and Müller RNAi screens is why only relatively few genes
re common to both lists of validated pathway regulators. Genes
entral to JAK/STAT signalling were identiﬁed in both screens
uggesting that both approaches are robust enough to identify pri-
ary pathway components and regulators such as socs36E and
tp61F. However, a majority of the genes identiﬁed by each screen
as not found in the other representing a population of ‘orphan’
egulators identiﬁed only under one set of screening conditions.
ltimately, differences in the results obtained in both screens are
ikely to arise from either biological differences in the screening
ystems, or experimental differences inherent in theRNAi approach
tself.
.1. Biological differences
The independent design and execution of the Baeg and Müller
AK/STATRNAi screens has resulted in a number of biological differ-
nces between the two strategies including differences in the cells
sed, the reporter and the method of pathway stimulation.
One obvious biological factor are differences in the transcrip-
omes of the two cell lines independently derived from the same
rganism. Indeed, comparison of the transcriptome of Kc167 and S2
ells (the parental cells fromwhich the S2-NP cells used in the Baeg
creen were derived) suggests that 5567 of the probe sets present
n the Affymetrix Drosophila Genome 1 chip were called present in
2 cells (40%) while 5773 are expressed in Kc167 cells (41%). In total,
214 genes were expressed in both Kc167 and S2 (6126 expressed
n either) giving an overlap in the present call between Kc167 and
2 cells of 85% (D. Sims, B. Baum, personal communication). Differ-
nces in the absolute levels of gene expression between cell lines as
ell as low level gene expression insufﬁcient to register as ‘present’
sing Afﬁmetrix technology would further increase the effective
ifferences in transcription between the cell lines used.
Although transcriptome data for the S2-NP cell line itself is not
vailable, its parental S2 strain, as well as Kc167 cells, show rela-
ively low levels of upd and higher levels of stat92E expression (data
etrieved from the FLIGHT database [62]). Consistent with the low
evels of upd in Kc167 cells, basal levels of pathway induction in the
üller screen were very low in the absence of ectopic ligand [53].
y contrast, S2-NP cells appear to express upd2 at a level sufﬁcient
or at leastmoderate levels of pathway induction [54]. Although the
unctional consequences of the different expression levels of both
athway components and regulators are unclear, it seems likely
hat differing transcription proﬁles may at least partly account for
he orphan regulators identiﬁed by the two screens.
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A further source for potential differences between the two
creens lies in the reporters used. While the Baeg screen used a
eporter based on the socs36E target gene, the Müller screen used a
ariant of the STAT92E dependent site previously identiﬁed within
he raf promoter [56]. Although the regulation of Drosophila raf
xpression includes a role for STAT92E, raf is expressed in many tis-
ues throughout development and is likely to be under the control
f a number of transcriptional regulators. By contrast, socs36E is one
f the strongest JAK/STAT pathway target genes in vivo and in cul-
ured cells (MPZ, unpublished). In addition, its expression appears
o be almost exclusively dependent on JAK/STAT pathway activ-
ty with an embryonic expression pattern closely matching that of
pd itself [10]. As such, it is possible that a reporter derived from
he raf promoter may exhibit requirements for co-factors or other
ignalling cascades that would not inﬂuence a reporter based on
he socs36E promoter. Ultimately, both groups used reporters con-
ainingmultimerisedversions of their respective STAT92E response
lements, taken out of chromosomal context and engineered into a
ransiently transfected plasmid for their primary screens. However,
t shouldbenoted that theMüller screen retested all potential inter-
cting dsRNAs using a second, non-multimerised socs36E derived
eporter [53] and should have therefore excluded multimerisation
rtefacts on this basis (see Table 1).
Probably one of the most signiﬁcant biological differences
etween the Baeg and Müller screens is the mechanism of pathway
ctivation employed. In the Müller screen, a plasmid constitu-
ively expressing the primary in vivo pathway ligand Upd was
o-transfected with the reporter before treatment with RNAi. This
ransfection occurred 5 days before the ultimate readout and
esulted in prolonged high-levels of pathway stimulation. By con-
rast the Baeg screen relied on the endogenous expression of Upd2
n S2-NP cells as a pathway stimulus, resulting in an equally pro-
onged, but lower level, of pathway stimulus. Because of these
ifferences in stimulation, high levels of ﬁreﬂy luciferase in the
üller screen resulted in knock down of positive pathway reg-
lators being readily identiﬁed while the available ‘headroom’ of
ncreased signalling caused by the knock down of negative regula-
ors was more constrained. By contrast, the lower levels of reporter
ctivity generated by endogenous Upd2 resulted in positive regu-
ator knock down that reduced reporter activity to levels difﬁcult
o statistically distinguish from the inherent noise of the system.
y contrast, removal of negative regulators which increase path-
ay activity are easily identiﬁed. This fundamental difference in
xperimentaldesign isprobablyavery signiﬁcant factor in the iden-
iﬁcation of ‘orphan’ regulators a hypothesis supported by the fact
hat 76% (92/121) of the Baeg screen hits represent negative regu-
ators while 73% (66 of 90) of the Müller screen hits are positively
cting factors.
Finally, the pathway signalling response to Upd (as used in the
üller screen) and Upd2 (as secreted by the S2-NP cells used in
he Baeg screen) may also differ for these two related, but clearly
ifferent ligands [7]. Indeed, re-screening of 29 positive regulators
rom the Baeg screen using Upd as a stimulus re-identiﬁed 27 as
ommon to both ligands [54], suggesting that at least some loci are
igand speciﬁc.
.2. Experimental differences
A further potential explanation for the differences between the
aeg and Müller screens are technical differences in the design,
xecution and post-screen statistical analysis of the data generated.
s with any complex experimental design, technical aspects are
ikely to inﬂuence the results ultimately obtained. One of the most
igniﬁcant of these is likely to be the post-screen statistical analysis
f the data sets generated and the ﬁltering undertaken.
t
d
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High-throughput experiments and the resulting data sets have
reviously been shown to be prone to artefacts. Discrepancies
etween microarray datasets analysing the same biological pro-
ess in yeast, but generated in different laboratories, represent
particularly striking example [63,64]. Furthermore, the overlap
n other genome-wide proteomic and protein–protein interaction
atasets can be very low (reviewed in [65]). As such, account-
ng for false positives and false negatives is of crucial importance
n any high-throughput experiment with one particularly signiﬁ-
ant factor being the different normalisation approaches used [66].
ost strikingly, different normalisation approaches can lead to the
ssignment of different regulatory roles for a candidate modulator.
or example, failure of reporter and control luciferase activities to
ollow ﬂuctuations in cell numbers or viability may lead to arte-
acts if activities are normalised to each other (Fig. 3B). Ideally, a
ontrol reporter will not respond to changes in signalling path-
ay activity and has a robust basal activity [67], criteria met by
oth screens which each used a similar co-reporter (Act-RL). How-
ver, in contrast to the Baeg screen, co-reporter activity was not
sed to normalise for transfection efﬁciency in the Müller screen.
nstead, transfection of cells ‘in batch’ before bathing with individ-
al dsRNAs allowed the use of the co-reporter as a separate ﬁlter
riterion to identify screening and viability artefacts. Table 2 shows
he phenotypes of overlapping hits in both screens and demon-
trates how some dsRNAs that were altered in both the reporter
nd co-reporter channels, do not show a change in signalling activ-
ty following FL/RL normalisation.Most of the identical phenotypes
etween Baeg and Müller screens, however, are robust to this kind
f normalisation (i.e. stat92E, dome, hop, CG17836, cdc2, apt, enok
ocs36E, ptp61F). Furthermore, different sensitivity and signal-to-
oise ratios in both screens could lead to different outcomes, and
s a consequence, the selected cut-off threshold can signiﬁcantly
ffect the ﬁnal candidate lists.
While the design and in silico optimisation of second and
hird generation collections of dsRNA molecules will undoubt-
dly improve library speciﬁcity, technical differences will probably
lways represent a potential source of false negatives.
Given the essentially unavoidable presence of false negative
alls, it is tempting to speculate thatmany of the JAK/STAT pathway
egulators identiﬁed by only one screen may have been ‘orphaned’
y such a false negative artefact in the other. Although this is
ertainly a potential explanation for some orphan interactors, indi-
idual validation and analysis of these loci will ultimately be
equired to determine if this is indeed the case. It is curious how-
ver that the strongest (mostly core components) have been found
n both screens, indicating that the false negative/positive rate
ight differ for functionally different subsets of the genes iden-
iﬁed.
. Potential optimisation of future screens
Although the results obtained from the two RNAi screens
escribed above have identiﬁed a range of genes for future analysis,
t is not clear what proportion of potential JAK/STAT pathway reg-
lators have been determined. Indeed, it would seem unlikely that
00+ additional ‘core’ components of a geneticallywell-studied sig-
allingpathway remain tobe identiﬁed.As such,manycomponents
dentiﬁed in a quantitative assay are likely to represent regula-
ory factors whose roles are highly context sensitive, although it
s unlikely that any cell-based assay could reproduce the complexi-
ies of pathway regulation and inter-pathway crosstalk that occurs
uring the course of embryonic and adult life.
Recent developments in the technology of genome-wide RNAi
creening in Drosophila cells suggest improvements that could
e achieved. These include the optimisation of assays to address
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peciﬁc aspects of pathway signalling, the use of improved RNAi
ibraries and the use of more sophisticated in silico analytical tools.
uch developments promise to not only extend, but also reﬁne and
alidate the existing inventory of putative JAK/STAT pathway reg-
lating genes.
.1. The next generation of cell culture-based RNAi screens
In the case of optimised screening approaches, a verywide range
f potential screens could be envisaged. These include modiﬁed
ranscriptional, luciferase-based reportersusingpromotersderived
rom various pathway target genes as well as different modes
f autocrine and paracrine stimulation with one or more of the
hree Drosophila Unpaired-like ligands using cell lines derived from
ultiple Drosophila tissues. Alternatively, more specialised high-
ontent assays of speciﬁc aspects of pathway activity may also be
ndertaken—these could include microscopic screens to automat-
cally quantify the nuclear translocation of activated STAT92E [68]
r assays to visualise thepre-dimerisation of theDomeless receptor
69]. In addition, biochemical assays of STAT92E phosphorylation,
NA binding or protein stability may also be viable when com-
ined with screens of smaller subsets of the available RNAi library.
combination of several of these readouts at the same time in a
ulti-parametric screenmayallowthedirect roleof a targetedgene
o be quickly assessed.
In addition to new screens, the use of new librarieswill also lead
o a signiﬁcant improvement in the quality of data generated from
enewed screening approaches. In particular, second generation
ibraries have been generated and optimised to avoid sequences
omologous to other genes and sequence motifs that might lead to
ff-target effects [70]. In such libraries, computer based approaches
ave been used to select dsRNAs which are diced in silico with the
esulting population of 21bp siRNAs individually compared to the
redicted transcriptome. The resulting data, when analysed in the
ight of advances in our understanding of the mechanistic basis of
NAi (reviewed in [71]), can be used to generate a prediction of the
trength of potential target gene knock down as well as the iden-
iﬁcation of transcripts potentially affected by off-target siRNAs
70].
Ultimately, third generation libraries will also be developed to
nclude multiple independent dsRNAs per gene, particularly where
n silicopredictions suggestdsRNAswithpotential off-target effects.
.2. Data analysis
Finally, experience gained during the analysis of the Müller
creen has underlined the signiﬁcant inﬂuence played by the
ost-screen in silico processing used to analyse the large datasets
enerated. Compared to other data sets in functional genomics,
ommon standards for RNAi experiments have not yet been estab-
ished. One such standard exists formicroarray experiments, which
llows for reproducible and independent data analysis. The MIAME
tandard represents the minimum information about a microarray
xperiment, which includes annotations about the experimental
esign and the microarray probes, the primary raw data of the
xperiments, as well as the normalised data and information about
ormalisation methods [72]. The RNAi Global Initiative is cur-
ently developing such a standardizedprotocol for RNAi screenings,
ermed MIARE for minimal information about RNAi experiments
http://www.miare.org), which will likely facilitate the establish-
ent of a public raw data repository as well as comparisons
etween different screens and the integration of other datasets in
eta-analyses.
Furthermore, reliable and robust statistical procedures are
mportant to identify interactors for downstream analysis.
a
a
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lthough statistical tools for the analysis of RNAi screens have been
eveloped [73,74], analysis approaches and software for multi-
arametric readouts are still needed. In particular, it is currently
nclear which normalisation method will identify bona ﬁde candi-
ates if several parameters, such as the activity of two luciferase
eporters, are measured at the same time. As such, it would be very
nteresting to ascertain the overlap between the two datasets of the
aeg and Müller screens using the same normalisation methods.
.3. Data validation
The potentially high rate of false-positives in RNAi screening
xperimentshasbeenpointedout andemphasises theneed to care-
ully validate the initial screening hits using independent reagents
n independent experiments [75]—for example by using more than
ne independent dsRNA targeting different regions of the mRNA.
A more rigorous validation of screening hits utilizes the poten-
ial evolutionary conservation of gene function, assuming that the
nockdownof gene activity in a conserved pathwaywould have the
ame functional consequences in different animal species [76,77].
he JAK/STAT pathway has been initially discovered in mammals
nd commercial tools for pathway analysis are available. These
nclude highly speciﬁc antibodies aswell as a range of siRNAs.More
mportantly, the JAK/STAT pathway is more complex with multiple
xtracellular ligands, JAKs and STATs, all of which contribute to dis-
inct biological responses. Using a vertebrate system with multiple
AK/STATpathways to validate interactors identiﬁed in an organism
ith only one JAK/STAT pathway may reveal differential roles for
athway modulators and would represent a powerful vindication
f the RNAi screening approaches described here.
Ultimately, the results of any screen only represent the identiﬁ-
ation of loci which potentially interact with the biological process
f interest. As such, lists generated by even the most carefully
esigned and executed cell culture-based screen merely represent
andidates awaiting in vivo validation. In this context, the recent
evelopment of libraries of transgenic Drosophila stocks expressing
nducible dsRNA constructs represents a potentially very valu-
ble tool [49]. Using such reagents, it will be possible to move
n from the cell-based screening described here to the detailed,
ene speciﬁc developmental genetic analysis that will ultimately
e required to fully investigate the loci identiﬁed. One potential
xample would be to combine the recently developed 10xSTAT-GFP
n vivo JAK/STAT pathway reporter [59] with the Gal4/UAS system
o express RNAi targeting putative pathway regulator genes.
. Conclusions
The two whole-genome RNAi screens discussed here have iden-
iﬁed a signiﬁcant number of positive and negatively acting loci
ith potential roles as JAK/STAT pathway regulators. Intriguingly,
ach screen appears to have enriched for a speciﬁc category of path-
ay regulator with negatively acting factors predominant in the
aeg data set and positively acting factors making up a large pro-
ortion of the Müller gene list. As such, it is likely that the results
enerated by the two screens are largely complementary to one
nother. It is important to stress however, that the results of any
arge-scale genetic screen are just a ﬁrst step in the characterisation
f potential pathway components. The results generated by both
enome-wide RNAi screens and more traditional forward genetic
pproaches all ultimately need to be validated by a detailed in vivo
nalysis and only then will the accuracy of the results generated by
NAi screens become apparent.
While the precise functions of many of the loci identiﬁed
emains to be determined, a number, including BRDW3and the his-
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one acetyl transferase enok, represent the homologues of human
isease genes already implicated in a range of leukaemias and
ymphomas [53]. By linking such disease genes with a signal
ransduction pathway the possibility to treat these diseases via
nterventionat otherpoints in thepathway ismadeavailable.While
uch approaches remain to be validated, it is hoped that compar-
tive, cross-species approaches will help to accelerate the rate at
hichunderstandingand insight intohumandisease canbegained.
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